Anti-GLDC Rabbit Monoclonal Antibody for WB, IHC-P, ELISA - P23378

Core Product Specifications and Parameters

Biological Background: GLDC Function and Localization

• GLDC (Glycine dehydrogenase (decarboxylating), mitochondrial) is the P protein component of the mitochondrial glycine cleavage system, catalyzing the degradation of glycine.
• The glycine cleavage system consists of four proteins: P protein (GLDC), T protein, H protein (GCSH), and L protein. GLDC binds the alpha-amino group of glycine via its pyridoxal phosphate cofactor, releases CO₂, and transfers the methylamine moiety to the H protein.
• GLDC is localized to the mitochondrion, consistent with its role in one‑carbon metabolism and energy production.
• The protein undergoes post‑translational acetylation, which may regulate its activity or stability.
• Disease variants in GLDC are associated with glycine encephalopathy (non‑ketotic hyperglycinemia), a disorder of glycine metabolism.
• The 3D structure of GLDC has been determined, providing insights into its catalytic mechanism and pyridoxal phosphate binding.

Experimental Guidance and Technical Tips

• The immunogen covers amino acids 580–749, ensuring recognition of the C‑terminal region of human GLDC.
• For western blotting, the predicted molecular weight is ~113 kDa; ensure appropriate gel percentage and transfer conditions for high‑molecular‑weight proteins.
• For IHC‑P, antigen retrieval may be required; validate in the relevant sample system.
• For ELISA, consider pairing with a capture antibody for sandwich ELISA development.
• Cross‑reactivity with mouse and rat allows use in rodent models; verify specificity in knockout samples if available.
• Since GLDC is mitochondrial, subcellular fractionation may enrich for mitochondrial proteins before analysis.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your one‑stop sourcing bridge for diagnostic manufacturers and research laboratories, offering raw materials for glycine metabolism and mitochondrial disorder research. We supply validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and can source rare‑target raw materials to support your IVD development from concept to clinic.